Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase

DM Slipetz, GP O'Neill, L Favreau, C Dufresne, M Gallant, Y Gareau, D Guay, M Labelle and KM Metters

Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada.

The human peripheral cannabinoid (CB2) receptor has been cloned by reverse transcription-polymerase chain reaction from human spleen RNA and expressed, to study both ligand binding characteristics and signal transduction pathways. Receptor binding assays used the aminoalkylindole [3H]Win 55212-2 and membranes from transiently transfected COS-M6 cells. Saturation analysis showed that [3H]Win 55212- 2 specific binding to the CB2 receptor was of high affinity, with a Kd of 2.1 +/- 0.2 nM (four experiments), and a high level of expression was attained, with a maximal number of saturable binding sites of 24.1 +/- 4.4 pmol/mg of protein (four experiments). The rates of association and dissociation for [3H]Win 55212-2 specific binding were both rapid when measured at 30 degrees. [3H]Win 55212-2 specific binding to the CB2 receptor was moderately enhanced by divalent and monovalent cations but was only slightly inhibited by guanosine-5'-O-(3-thio)- triphosphate. Competition for [3H]Win 55212-2 specific binding to the CB2 receptor was stereoselective, with the following rank order of potency for the more active stereoisomers: HU-210 > (-)-CP-55940 approximately Win 55212-2 >> (-)delta 9-THC > anandamide. The signaling pathway of the human CB2 receptor was investigated in a CB2-CHO-K1 stable cell line. CB2 receptor activation by cannabinoid agonists inhibited forskolin-induced cAMP production in a concentration- dependent and stereoselective manner but did not increase either cAMP production or Ca2+ mobilization in fura-2/acetoxymethyl ester-loaded CB2-CHO-K1 cells. The CB2 receptor-mediated inhibition of forskolin- induced cAMP production was abolished by pretreatment of the cells with 10 ng/ml pertussis toxin. These results demonstrate that the CB2 receptor is functionally coupled to inhibition of adenylyl cyclase activity via a pertussis toxin-sensitive G protein.

Volume 48, Issue 2, pp. 352-361, 08/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				D. Matas, A. Juknat, M. Pietr, Y. Klin, and Z. Vogel Anandamide Protects from Low Serum-induced Apoptosis via Its Degradation to Ethanolamine J. Biol. Chem., March 16, 2007; 282(11): 7885 - 7892. [Abstract] [Full Text] [PDF]

				B. Kraft and H. G. Kress Indirect CB2 Receptor and Mediator-Dependent Stimulation of Human Whole-Blood Neutrophils by Exogenous and Endogenous Cannabinoids J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 641 - 647. [Abstract] [Full Text] [PDF]

				N. M. Curran, B. D. Griffin, D. O'Toole, K. J. Brady, S. N. Fitzgerald, and P. N. Moynagh The Synthetic Cannabinoid R(+)WIN 55,212-2 Inhibits the Interleukin-1 Signaling Pathway in Human Astrocytes in a Cannabinoid Receptor-independent Manner J. Biol. Chem., October 28, 2005; 280(43): 35797 - 35806. [Abstract] [Full Text] [PDF]

				B. L. F. Kaplan, C. E. Rockwell, and N. E. Kaminski Evidence for Cannabinoid Receptor-Dependent and -Independent Mechanisms of Action in Leukocytes J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1077 - 1085. [Abstract] [Full Text] [PDF]

				A. Franklin, S. Parmentier-Batteur, L. Walter, D. A. Greenberg, and N. Stella Palmitoylethanolamide Increases after Focal Cerebral Ischemia and Potentiates Microglial Cell Motility J. Neurosci., August 27, 2003; 23(21): 7767 - 7775. [Abstract] [Full Text] [PDF]

				R. Anikwue, J. W. Huffman, Z. L. Martin, and S. P. Welch Decrease in Efficacy and Potency of Nonsteroidal Anti-Inflammatory Drugs by Chronic Delta 9-Tetrahydrocannabinol Administration J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 340 - 346. [Abstract] [Full Text] [PDF]

				A. L. Ulfers, J. L. McMurry, A. Miller, L. Wang, D. A. Kendall, and D. F. Mierke Cannabinoid receptor-G protein interactions: G{alpha}i1-bound structures of IC3 and a mutant with altered G protein specificity Protein Sci., October 1, 2002; 11(10): 2526 - 2531. [Abstract] [Full Text] [PDF]

				A. C. Howlett, F. Barth, T. I. Bonner, G. Cabral, P. Casellas, W. A. Devane, C. C. Felder, M. Herkenham, K. Mackie, B. R. Martin, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev., June 1, 2002; 54(2): 161 - 202. [Abstract] [Full Text] [PDF]

				C. S. Breivogel and S. R. Childers Cannabinoid Agonist Signal Transduction in Rat Brain: Comparison of Cannabinoid Agonists in Receptor Binding, G-Protein Activation, and Adenylyl Cyclase Inhibition J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 328 - 336. [Abstract] [Full Text]

				Y. Chen and J. Buck Cannabinoids Protect Cells from Oxidative Cell Death: A Receptor-Independent Mechanism J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 807 - 812. [Abstract] [Full Text]

				W. Gonsiorek, C. Lunn, X. Fan, S. Narula, D. Lundell, and R. W. Hipkin Endocannabinoid 2-Arachidonyl Glycerol Is a Full Agonist through Human Type 2 Cannabinoid Receptor: Antagonism by Anandamide Mol. Pharmacol., May 1, 2000; 57(5): 1045 - 1050. [Abstract] [Full Text]

				M. Glass and J. K. Northup Agonist Selective Regulation of G Proteins by Cannabinoid CB1 and CB2 Receptors Mol. Pharmacol., December 1, 1999; 56(6): 1362 - 1369. [Abstract] [Full Text]

				C.-n. Chin, J. W. Murphy, J. W. Huffman, and D. A. Kendall The Third Transmembrane Helix of the Cannabinoid Receptor Plays a Role in the Selectivity of Aminoalkylindoles for CB2, Peripheral Cannabinoid Receptor J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 837 - 844. [Abstract] [Full Text]

				M. E. Nuttall, J. C. Lee, P. R. Murdock, A. M. Badger, F.-L. Wang, J. T. Laydon, G. A. Hofmann, G. R. Pettman, J. A. Lee, A. Parihar, et al. Amphibian Melanophore Technology as a Functional Screen for Antagonists of G-Protein Coupled 7-Transmembrane Receptors J Biomol Screen, October 1, 1999; 4(5): 269 - 277. [Abstract] [PDF]

				C. J. Hillard, S. Manna, M. J. Greenberg, R. DiCamelli, R. A. Ross, L. A. Stevenson, V. Murphy, R. G. Pertwee, and W. B. Campbell Synthesis and Characterization of Potent and Selective Agonists of the Neuronal Cannabinoid Receptor (CB1) J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1427 - 1433. [Abstract] [Full Text]

				J. Wang, B. C. Paria, S. K. Dey, and D. R. Armant Stage-Specific Excitation of Cannabinoid Receptor Exhibits Differential Effects on Mouse Embryonic Development Biol Reprod, April 1, 1999; 60(4): 839 - 844. [Abstract] [Full Text]

				Q. Tao, S. D. McAllister, J. Andreassi, K. W. Nowell, G. A. Cabral, D. P. Hurst, K. Bachtel, M. C. Ekman, P. H. Reggio, and M. E. Abood Role of a Conserved Lysine Residue in the Peripheral Cannabinoid Receptor (CB2): Evidence for Subtype Specificity Mol. Pharmacol., March 1, 1999; 55(3): 605 - 613. [Abstract] [Full Text]

				M. Portier, M. Rinaldi-Carmona, F. Pecceu, T. Combes, C. Poinot-Chazel, B. Calandra, F. Barth, G. L. Fur, and P. Casellas SR 144528, an Antagonist for the Peripheral Cannabinoid Receptor that Behaves as an Inverse Agonist J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 582 - 589. [Abstract] [Full Text]

				M. Rinaldi-Carmona, A. Le Duigou, D. Oustric, F. Barth, M. Bouaboula, P. Carayon, P. Casellas, and G. Le Fur Modulation of CB1 Cannabinoid Receptor Functions after a Long-Term Exposure to Agonist or Inverse Agonist in the Chinese Hamster Ovary Cell Expression System J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1038 - 1047. [Abstract] [Full Text]

				P. Carayon, J. Marchand, D. Dussossoy, J.-M. Derocq, O. Jbilo, A. Bord, M. Bouaboula, S. Galiegue, P. Mondiere, G. Penarier, et al. Modulation and Functional Involvement of CB2 Peripheral Cannabinoid Receptors During B-Cell Differentiation Blood, November 15, 1998; 92(10): 3605 - 3615. [Abstract] [Full Text] [PDF]

				C. Sánchez, I. Galve-Roperh, D. Rueda, and M. Guzmán Involvement of Sphingomyelin Hydrolysis and the Mitogen-Activated Protein Kinase Cascade in the Delta 9-Tetrahydrocannabinol-Induced Stimulation of Glucose Metabolism in Primary Astrocytes Mol. Pharmacol., November 1, 1998; 54(5): 834 - 843. [Abstract] [Full Text]

				C. S. Breivogel, D. E. Selley, and S. R. Childers Cannabinoid Receptor Agonist Efficacy for Stimulating [35S]GTPgamma S Binding to Rat Cerebellar Membranes Correlates with Agonist-induced Decreases in GDP Affinity J. Biol. Chem., July 3, 1998; 273(27): 16865 - 16873. [Abstract] [Full Text] [PDF]

				Q. Tao and M. E. Abood Mutation of a Highly Conserved Aspartate Residue in the Second Transmembrane Domain of the Cannabinoid Receptors, CB1 and CB2, Disrupts G-Protein Coupling J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 651 - 658. [Abstract] [Full Text]

				M. Rinaldi-Carmona, F. Barth, J. Millan, J.-M. Derocq, P. Casellas, C. Congy, D. Oustric, M. Sarran, M. Bouaboula, B. Calandra, et al. SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 644 - 650. [Abstract] [Full Text]

				P. Valk, S. Verbakel, Y. Vankan, S. Hol, S. Mancham, R. Ploemacher, A. Mayen, B. Lowenberg, and R. Delwel Anandamide, a Natural Ligand for the Peripheral Cannabinoid Receptor Is a Novel Synergistic Growth Factor for Hematopoietic Cells Blood, August 15, 1997; 90(4): 1448 - 1457. [Abstract] [Full Text] [PDF]

				M. Bayewitch, M.-H. Rhee, T. Avidor-Reiss, A. Breuer, R. Mechoulam, and Z. Vogel (-)-Delta^9-Tetrahydrocannabinol Antagonizes the Peripheral Cannabinoid Receptor-mediated Inhibition of Adenylyl Cyclase J. Biol. Chem., April 26, 1996; 271(17): 9902 - 9905. [Abstract] [Full Text] [PDF]

				D. Shire, B. Calandra, M. Delpech, X. Dumont, M. Kaghad, Gér. Le Fur, D. Caput, and P. Ferrara Structural Features of the Central Cannabinoid CB1 Receptor Involved in the Binding of the Specific CB1 Antagonist SR 141716A J. Biol. Chem., March 22, 1996; 271(12): 6941 - 6946. [Abstract] [Full Text] [PDF]